- Home
- SERV vs TNGX Comparison
SERV vs TNGX Comparison
Compare SERV & TNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SERV
- TNGX
- Stock Information
- Founded
- SERV 2017
- TNGX 2014
- Country
- SERV United States
- TNGX United States
- Employees
- SERV N/A
- TNGX N/A
- Industry
- SERV Industrial Specialties
- TNGX Biotechnology: Pharmaceutical Preparations
- Sector
- SERV Consumer Discretionary
- TNGX Health Care
- Exchange
- SERV Nasdaq
- TNGX Nasdaq
- Market Cap
- SERV 609.5M
- TNGX 723.0M
- IPO Year
- SERV N/A
- TNGX N/A
- Fundamental
- Price
- SERV $10.01
- TNGX $6.53
- Analyst Decision
- SERV Strong Buy
- TNGX Strong Buy
- Analyst Count
- SERV 4
- TNGX 5
- Target Price
- SERV $17.00
- TNGX $10.50
- AVG Volume (30 Days)
- SERV 5.3M
- TNGX 1.9M
- Earning Date
- SERV 08-12-2025
- TNGX 08-05-2025
- Dividend Yield
- SERV N/A
- TNGX N/A
- EPS Growth
- SERV N/A
- TNGX N/A
- EPS
- SERV N/A
- TNGX N/A
- Revenue
- SERV $1,306,237.00
- TNGX $40,990,000.00
- Revenue This Year
- SERV $284.61
- TNGX N/A
- Revenue Next Year
- SERV $580.91
- TNGX N/A
- P/E Ratio
- SERV N/A
- TNGX N/A
- Revenue Growth
- SERV 17.26
- TNGX 10.09
- 52 Week Low
- SERV $4.66
- TNGX $1.03
- 52 Week High
- SERV $24.35
- TNGX $12.02
- Technical
- Relative Strength Index (RSI)
- SERV N/A
- TNGX 60.33
- Support Level
- SERV N/A
- TNGX $6.36
- Resistance Level
- SERV N/A
- TNGX $7.11
- Average True Range (ATR)
- SERV 0.00
- TNGX 0.52
- MACD
- SERV 0.00
- TNGX -0.13
- Stochastic Oscillator
- SERV 0.00
- TNGX 53.15
About SERV Serve Robotics Inc. Common Stock
Serve Robotics Inc is developing next-generation robots for last-mile delivery services. It design, develop and operate low-emissions robots on AI-powered robotics mobility platform, that serve people in public spaces, starting with food delivery. Its first product is a zero-emission robot that serves people in public areas, Starting with food delivery. It has developed an AI-robotics mobility platform, with last-mile delivery in cities as its first application.
About TNGX Tango Therapeutics Inc.
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.